Somatic TP53 mosaicism

Overview

Somatic TP53 mosaicism is a genetic change that affects some cells in the body, but not all. This is different from inherited conditions where every cell typically carries the genetic alteration. In somatic mosaicism, the genetic change happens after conception, during early development, or even later in life [PMID:37577319]. The TP53 gene is crucial for preventing tumours, so when it is altered in a mosaic pattern, it can increase the risk of various cancers developing over a person's lifetime. The specific pattern and distribution of these altered cells can influence the types of cancers that might occur and their onset.

Understanding somatic TP53 mosaicism is important because it represents a different mechanism for cancer predisposition than germline (inherited) genetic changes. While inherited TP53 changes cause Li-Fraumeni syndrome, somatic mosaicism involves a more localised or patchy presence of the alteration. The clinical presentation can vary depending on where in the body the cells with the altered TP53 gene are located and how widespread they are. It is considered a rare condition, and its exact prevalence is not well established.

Symptoms & clinical features

Somatic TP53 mosaicism itself does not typically cause direct symptoms but acts as a predisposition for developing certain cancers. Therefore, the 'symptoms' are those associated with the cancers that may arise. These can vary widely depending on the cancer type, location, and stage.

Individuals with somatic TP53 mosaicism may experience an earlier onset of certain cancers compared to the general population, or develop multiple primary tumours over their lifetime. The types of cancers can include, but are not limited to, soft tissue sarcomas, osteosarcomas, breast cancer, brain tumours, adrenocortical carcinoma, and leukaemia. Symptoms might include a new lump or mass, unexplained pain, weight loss, fatigue, or changes in bowel or bladder habits, which are common signs of cancer [PMID:34226199]. Due to the mosaic nature of the genetic change, the clinical presentation can be highly variable between affected individuals.

Video: Is cancer in your genes?

Affected organs

The TP53 gene plays a fundamental role in controlling cell growth and division throughout the body. Consequently, when somatic TP53 mosaicism is present, it can potentially affect almost any organ system. However, the specific organs most commonly associated with cancer development in this context include soft tissues, bones, breasts, the brain, adrenal glands, and blood-forming tissues [PMID:34226199].

The distribution of the mosaic cells largely dictates which organs are at higher risk. If the genetic change occurred very early in development, a broader range of tissues might carry the altered TP53 gene. If it occurred later or in a more localised way, the cancer risk might be more confined to specific areas. The varied cancer types seen with TP53 alterations reflect the widespread importance of the gene in maintaining genomic stability across different cell types.

Multiple body systems

Systemic involvement

Cellular impact

Mechanism at cellular level

Risks & severity

Somatic TP53 mosaicism is associated with an increased lifetime risk of developing various cancers. The severity and specific cancer risks can depend on several factors, including the proportion of cells carrying the TP53 alteration, the specific type of genetic change, and the timing of its occurrence during development [PMID:37577319]. Generally, a higher proportion of cells with the altered TP53 gene may correlate with a higher cancer risk and potentially an earlier age of cancer onset.

Unlike inherited Li-Fraumeni syndrome, where cancer risks are well-defined, the specific risk profile for somatic TP53 mosaicism is more complex and less comprehensively understood. However, individuals with this condition are typically considered to have an elevated risk of developing cancers such as sarcomas, breast cancer, brain tumours, and adrenocortical carcinoma. Regular surveillance for these cancers is often recommended to facilitate early detection and intervention.

Genetic causes

Somatic TP53 mosaicism results from a genetic alteration in the TP53 gene that arises in some cells after fertilisation. The TP53 gene provides instructions for making the p53 protein, which is often called the 'guardian of the genome' because of its critical role in preventing tumour formation. The p53 protein acts as a tumour suppressor by initiating DNA repair, halting cell division to allow for repair, or triggering programmed cell death (apoptosis) if DNA damage is too severe [PMID:34226199].

When the TP53 gene is altered, the p53 protein may not function correctly, or its production might be reduced. This can impair the cell's ability to respond appropriately to DNA damage, leading to the accumulation of further genetic errors and uncontrolled cell growth, which can ultimately lead to cancer. In somatic mosaicism, these TP53 alterations are not present in every cell from birth but develop in a subset of cells, creating a mixture of cells with and without the genetic change.

• TP53
  tumor protein p53
  TP53 encodes tumour protein p53, a critical regulator of cell division and DNA repair often called the guardian of the genome.

Inheritance pattern

Somatic TP53 mosaicism is not inherited in the typical sense; it is a somatic condition. This means the genetic alteration in the TP53 gene occurs in some body cells after conception, rather than being passed down from a parent to a child through germ (sperm or egg) cells. Therefore, affected individuals do not typically pass this specific mosaic genetic change on to their children.

However, it's important to distinguish somatic mosaicism from inherited (germline) TP53 alterations, which cause Li-Fraumeni syndrome and are inherited in an autosomal dominant pattern. If an individual has a somatic TP53 mosaicism, their children would generally not be at an increased risk of inheriting that specific mosaic alteration. Genetic counselling can help clarify the implications for family members and differentiate between somatic and germline TP53 changes.

Diagnosis & testing

Diagnosing somatic TP53 mosaicism typically involves genetic testing, particularly when there is a suspicion of a cancer predisposition that doesn't fit a clear inherited pattern. The presence of multiple primary cancers, early-onset cancers, or certain types of rare cancers can prompt suspicion. Since the genetic alteration is mosaic, specialised genetic testing techniques with high sensitivity are often required to detect the variant in a proportion of cells [PMID:37577319].

Referral to a clinical genetics service is usually the first step for individuals suspected of having this condition. Genetic testing may involve analysing DNA from a blood sample, tumour tissue, or other relevant tissues, sometimes using advanced sequencing methods like next-generation sequencing. The NHS Genomic Medicine Service (GMS) provides a pathway for genetic testing, often initiated via an R-code referral from a clinician, which helps confirm the diagnosis and guides appropriate clinical management and surveillance strategies.

Management & lifestyle

Managing individuals with somatic TP53 mosaicism primarily focuses on early detection and treatment of potential cancers, as there is currently no way to correct the genetic alteration in affected cells. The management strategy often involves regular cancer surveillance, tailored to the specific cancer risks identified. This may include frequent physical examinations, blood tests, imaging studies (such as MRI scans), and endoscopic procedures, depending on the organs at risk [PMID:34226199].

Treatment for any diagnosed cancers will follow standard oncology guidelines, which may include surgery, chemotherapy, and radiotherapy. It is crucial for individuals to be part of a multidisciplinary team including oncologists and geneticists. Lifestyle considerations, such as avoiding known carcinogens and maintaining a healthy lifestyle, are generally recommended, though specific evidence for their impact in this rare condition is limited. Genetic counsellors play a vital role in explaining the condition, its implications, and guiding individuals through the NHS care pathway.

UK care pathway

In the UK, individuals suspected of having somatic TP53 mosaicism would typically be referred to a clinical genetics service within the NHS Genomic Medicine Service (GMS). This referral often originates from a general practitioner or a specialist, such as an oncologist, if there are concerns about an unusual cancer presentation or family history. Genetic counsellors are integral to this pathway, providing information, support, and helping families understand the implications of genetic test results.

Genetic testing for TP53 alterations falls under specific NHS R-codes, which ensure that appropriate and high-quality testing is performed. These codes help guide clinicians in ordering the correct tests and ensure consistency across the NHS. Following diagnosis, individuals are usually enrolled in a surveillance programme managed by specialist teams to monitor for early signs of cancer.

Related conditions

Somatic TP53 mosaicism should be distinguished from other conditions associated with TP53 alterations. The most well-known is Li-Fraumeni syndrome (LFS), which is caused by an inherited (germline) pathogenic variant in the TP53 gene, meaning every cell in the body carries the alteration. LFS typically presents with a clear family history of multiple early-onset cancers and specific tumour types.

Another related concept is de novo germline TP53 variants, where a new TP53 pathogenic variant arises in the egg or sperm cell or very early in development, leading to LFS in an individual without a family history. Somatic TP53 mosaicism, however, differs because the TP53 alteration is only present in a proportion of cells and is not typically passed down through generations, making it a distinct clinical entity with its own considerations for diagnosis and management.

• Li-Fraumeni syndrome
  Cancer Predisposition
  Shares 1 gene

Frequently asked questions